The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
 
Raymond P. Perez
Consulting or Advisory Role - Pharmaceutical Research Associates
Research Funding - Agensys (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Dompé Farmaceutici (Inst); Genentech/Roche (Inst); Immunogen (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Onyx (Inst); Regeneron (Inst); TetraLogic Pharmaceuticals (Inst)
 
Matthew John Riese
Consulting or Advisory Role - Abbvie; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb; Incyte
 
Karl D. Lewis
Consulting or Advisory Role - Roche; Sun Pharma
Research Funding - Amgen; Incyte; Roche
 
Mansoor N. Saleh
Honoraria - Genentech
Speakers' Bureau - Gilead Sciences; Novartis
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Jordan Berlin
Consulting or Advisory Role - Aduro Biotech; ARMO BioSciences; Boston Biomedical; Celgene; Cornerstone Pharmaceuticals; EMD Serono; Exelixis; Five Prime Therapeutics; Genentech/Roche; Janssen Oncology; Opsona Therapeutics; Pharmacyclics; Pierre Fabre; Symphony Evolution; Vertex
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Boston Biomedical; Celgene; Genentech/Roche; Janssen Oncology; vertex
Other Relationship - AstraZeneca; Momenta Pharmaceuticals; Symphony Evolution
 
James J. Lee
Consulting or Advisory Role - Genentech
Research Funding - Merck
 
Sutapa Mukhopadhyay
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Li Zhou
Employment - Incyte; Merck (I)
Stock and Other Ownership Interests - Incyte
 
Gul Serbest
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)